Stock Scorecard



Stock Summary for Ovid Therapeutics Inc (OVID) - $2.46 as of 3/26/2026 9:47:14 PM EST

Total Score

9 out of 30

Safety Score

19 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for OVID

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for OVID

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for OVID

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for OVID

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for OVID (19 out of 100)

Stock Price Rating (Max of 10) 3
Historical Stock Price Rating (Max of 10) 2
Stock Price Trend (Max of 10) 9
Book Value (Max of 10) 1
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 0
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 9
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) -10

Latest News for for OVID

Ovid Therapeutics (NASDAQ:OVID) Receives Consensus Recommendation of "Buy" from Brokerages 3/26/2026 6:41:00 AM
Ovid Therapeutics (NASDAQ: OVID) chair exercises 47,333-share warrant at $1.40 3/26/2026 1:41:00 AM
Investors pour $60M into Ovid Therapeutics to advance seizure drugs 3/25/2026 11:39:00 AM
If You Invested $1,000 in Ovid Therapeutics Inc (OVID) 3/22/2026 11:09:00 PM
Wall Street Zen Upgrades Ovid Therapeutics (NASDAQ:OVID) to Hold 3/21/2026 6:40:00 AM
Ovid Therapeutics Sells Ganaxolone Royalty Rights for $7M to Immedica Pharma 3/21/2026 12:40:00 AM
B.Riley reiterates Buy on Ovid Therapeutics stock, $5 target By Investing.com 3/20/2026 11:39:00 PM
Ovid Therapeutics Stock Surges on Positive Drug Trial Data and Financing Plans 3/20/2026 6:39:00 PM
A Look At Ovid Therapeutics (OVID) Valuation After OV329 Trial Update And US$60 Million Financing 3/20/2026 2:39:00 PM
Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results 3/20/2026 9:40:00 AM

Financial Details for OVID

Company Overview

Ticker OVID
Company Name Ovid Therapeutics Inc
Country N/A
Description Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medications for patients and families with neurological disorders in the United States. The company is headquartered in New York, New York.
Sector Name HEALTHCARE
Industry Name BIOTECHNOLOGY
Most Recent Quarter 12/31/2025
Next Earnings Date 5/12/2026

Stock Price History

Last Day Price 2.46
Price 4 Years Ago 1.86
Last Day Price Updated 3/26/2026 9:47:14 PM EST
Last Day Volume 1,564,118
Average Daily Volume 3,417,937
52-Week High 2.72
52-Week Low 0.24
Last Price to 52 Week Low 925.00%

Valuation Measures

Trailing PE N/A
Industry PE 38.69
Sector PE 78.04
5-Year Average PE -2.57
Free Cash Flow Ratio 24.60
Industry Free Cash Flow Ratio 15.55
Sector Free Cash Flow Ratio 21.01
Current Ratio Most Recent Quarter 10.91
Total Cash Per Share 0.10
Book Value Per Share Most Recent Quarter 0.63
Price to Book Ratio 4.17
Industry Price to Book Ratio 70.86
Sector Price to Book Ratio 22.56
Price to Sales Ratio Twelve Trailing Months 50.87
Industry Price to Sales Ratio Twelve Trailing Months 13.17
Sector Price to Sales Ratio Twelve Trailing Months 26.98
Analyst Buy Ratings 11
Analyst Strong Buy Ratings 0

Share Statistics

Total Shares Outstanding 131,875,000
Market Capitalization 324,412,500
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth 34.12%
Reported EPS 12 Trailing Months -0.23
Reported EPS Past Year -0.31
Reported EPS Prior Year -0.38
Net Income Twelve Trailing Months -17,413,000
Net Income Past Year -17,414,000
Net Income Prior Year -26,433,000
Quarterly Revenue Growth YOY 845.00%
5-Year Revenue Growth -10.48%
Operating Margin Twelve Trailing Months -1,712.00%

Balance Sheet

Total Cash Most Recent Quarter 13,153,000
Total Cash Past Year 13,153,000
Total Cash Prior Year 26,301,000
Net Cash Position Most Recent Quarter 13,153,000
Net Cash Position Past Year 13,153,000
Long Term Debt Past Year 0
Long Term Debt Prior Year 0
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 130,660,000
Total Stockholder Equity Prior Year 68,226,000
Total Stockholder Equity Most Recent Quarter 130,660,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -38,356,000
Free Cash Flow Per Share Twelve Trailing Months -0.29
Free Cash Flow Past Year -38,334,000
Free Cash Flow Prior Year -56,027,000

Options

Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 0.00
MACD Signal 0.00
20-Day Bollinger Lower Band 0.00
20-Day Bollinger Middle Band 0.00
20-Day Bollinger Upper Band 0.00
Beta 0.16
RSI 0.00
50-Day SMA 0.00
150-Day SMA 0.00
200-Day SMA 0.00

System

Modified 3/26/2026 8:19:53 PM EST